Back to results
US 2020/0206218 A1Published application
Pharmaceutical compositions
AssigneeCharleston Laboratories, Inc.
InventorsPaul Bosse, John Ameling, Bernard Schachtel, Ray Takigiku
Life of this patent
Estimating the term…
Abstract
Methods and compositions are provided which comprise effective amounts of an analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.
Claims22
A method for treating pain, the method comprising orally administering to a subject in need thereof:
- a) first solid matrix, wherein the first solid matrix comprises an effective amount of a first pharmaceutically active agent for treating or preventing pain in a subject in need thereof, wherein the first pharmaceutically active agent comprises a triptan, and wherein the triptan comprises naratriptan, almotriptan, sumatriptan, zolmitriptan, eletriptan, frovatriptan, or rizatriptan;
- and
- b) a second solid matrix, wherein the solid second matrix comprises an effective amount of promethazine or a pharmaceutically acceptable salt thereof for preventing or reducing nausea or vomiting, and wherein the second matrix is an immediate release matrix.
(canceled)
A method for treating pain, the method comprising orally administering to a subject in need thereof:
- a) a first solid matrix, wherein the first solid matrix comprises an effective amount of a first pharmaceutically active agent for treating or preventing pain in a subject in need thereof, wherein the first pharmaceutically active agent comprises:
- i) an ergot, and wherein the ergot comprises ergotamine, methysergide, or zonisamide;
- ii) a beta blocker, wherein the beta blocker comprises acebutolol, arotinolol, atenolol, betaxolol, bisoprolol, butoxamine, carvedilol, carteolol, esmolol, carteolol, carvedilol, labetalol, levobunolol, mepindolol, metoprolol, nebivolol, nadolol, oxprenolol, penbutolol, propranolol, pindolol, sotalol, or timolol;
- or
- iii) a calcitonin-gene-related peptide (CGRP) receptor antagonist, and wherein the CGRP receptor antagonist comprises MK-0974, CGRP8-37, BIBN 4096 BS, quinine, nitrobenzamide, 4-oxobutanamide, a cyclopropane derivative, or a benzimidazolinyl piperidine;
- and
- b) a second solid matrix, wherein the solid second matrix comprises an effective amount of promethazine or a pharmaceutically acceptable salt thereof for preventing or reducing nausea or vomiting, and wherein the second matrix is an immediate release matrix.
4 more elements
(canceled)
Dependencies are inferred from the claim text.